$MLTX
MoonLake Immunotherapeutics

2023 Q1 Form 10-Q Financial Statement

#000182158623000012 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.516M $5.687M
YoY Change -3.01%
% of Gross Profit
Research & Development $7.415M $10.25M
YoY Change -27.69%
% of Gross Profit
Depreciation & Amortization $3.290K $2.488K
YoY Change 32.23%
% of Gross Profit
Operating Expenses $12.93M $2.712M
YoY Change 376.92% 2781.2%
Operating Profit -$12.93M -$15.94M
YoY Change -18.89%
Interest Expense $7.770K
YoY Change
% of Operating Profit
Other Income/Expense, Net $723.6K $69.51K
YoY Change 940.99%
Pretax Income -$12.21M -$2.704M
YoY Change 351.53% 3444.0%
Income Tax $11.01K $7.330K
% Of Pretax Income
Net Earnings -$9.005M -$15.88M
YoY Change -43.29% 4415.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23 -$3.17
Diluted Earnings Per Share -$0.23 -$183.3K
COMMON SHARES
Basic Shares Outstanding 39.06M shares 5.014M shares
Diluted Shares Outstanding 39.06M shares 5.014M shares

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.03M $23.34K
YoY Change 269947.97% -98.01%
Cash & Equivalents $50.13M $8.834M
Short-Term Investments $12.90M
Other Short-Term Assets $400.0K $101.1M
YoY Change -99.6% 34819.01%
Inventory
Prepaid Expenses $3.076M
Receivables
Other Receivables $378.4K
Total Short-Term Assets $66.50M $116.2M
YoY Change -42.75% 7857.8%
LONG-TERM ASSETS
Property, Plant & Equipment $46.10K $100.0K
YoY Change -53.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $115.1M
YoY Change 0.02%
Other Assets
YoY Change
Total Long-Term Assets $292.4K $115.1M
YoY Change -99.75% 0.02%
TOTAL ASSETS
Total Short-Term Assets $66.50M $116.2M
Total Long-Term Assets $292.4K $115.1M
Total Assets $66.80M $231.2M
YoY Change -71.11% 98.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.600M $3.400M
YoY Change 5.88%
Accrued Expenses $3.500M $5.798M
YoY Change -39.63% 9563.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $150.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.279M $202.8M
YoY Change -96.41% 337883.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $400.0K $4.025M
YoY Change -90.06% 0.0%
Total Long-Term Liabilities $405.3K $4.025M
YoY Change -89.93% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.279M $202.8M
Total Long-Term Liabilities $405.3K $4.025M
Total Liabilities $7.685M $206.8M
YoY Change -96.28% 4962.8%
SHAREHOLDERS EQUITY
Retained Earnings -$89.66M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $42.00M $24.40M
YoY Change
Total Liabilities & Shareholders Equity $66.80M $231.2M
YoY Change -71.11% 98.48%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$9.005M -$15.88M
YoY Change -43.29% 4415.6%
Depreciation, Depletion And Amortization $3.290K $2.488K
YoY Change 32.23%
Cash From Operating Activities -$9.024M -$793.5K
YoY Change 1037.37% 636.04%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $16.01K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $19.65M
YoY Change
Cash From Investing Activities $19.65M -$16.01K
YoY Change -122826.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 150.0K
YoY Change -100.0% -358.35%
NET CHANGE
Cash From Operating Activities -$9.024M -793.5K
Cash From Investing Activities $19.65M -$16.01K
Cash From Financing Activities $0.00 150.0K
Net Change In Cash $10.62M -643.5K
YoY Change -1751.03% 287.95%
FREE CASH FLOW
Cash From Operating Activities -$9.024M -$793.5K
Capital Expenditures $0.00 $16.01K
Free Cash Flow -$9.024M -$809.5K
YoY Change 1014.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001821586
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39630
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
MOONLAKE IMMUNOTHERAPEUTICS
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1711963
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Dorfstrasse 29
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
CY2023Q1 dei Entity Address Country
EntityAddressCountry
CH
CY2023Q1 dei City Area Code
CityAreaCode
41
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
415108022
CY2023Q1 dei Security12b Title
Security12bTitle
Class A ordinary share, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
MLTX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50129197 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39505627 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
12920960 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
32609108 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
378445 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
217129 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3075862 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4179468 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
66504464 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
76511332 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
246256 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
282580 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46099 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49389 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
292355 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
331969 usd
CY2023Q1 us-gaap Assets
Assets
66796819 usd
CY2022Q4 us-gaap Assets
Assets
76843301 usd
CY2023Q1 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
3827403 usd
CY2022Q4 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
254972 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
155173 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
153629 usd
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3296839 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7256845 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7279415 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7665446 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91081 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
128951 usd
CY2023Q1 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
314174 usd
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
282206 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
405255 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
411157 usd
CY2023Q1 us-gaap Liabilities
Liabilities
7684670 usd
CY2022Q4 us-gaap Liabilities
Liabilities
8076603 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131308849 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129192291 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89655068 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80650212 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
340108 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
350946 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
41999160 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
48898296 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
17112989 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
19868402 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
59112149 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68766698 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66796819 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76843301 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7415097 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10454948 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5516469 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5487368 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
12931566 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
15942316 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12931566 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15942316 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
723589 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
69506 usd
CY2023Q1 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-12207977 usd
CY2022Q1 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-15872810 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11010 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7332 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12218987 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-15880142 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9004856 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15880142 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3214131 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
24472 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
-42144 usd
CY2022Q1 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
266269 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17672 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
266269 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12236659 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-15613873 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9017481 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15613873 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-3219178 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-11645007 usd
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1992662 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-15880142 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
266269 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-25266218 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68766698 usd
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
2577187 usd
CY2023Q1 mnlk Adjustments To Additional Paid In Capital Stamp Duty Fees
AdjustmentsToAdditionalPaidInCapitalStampDutyFees
4923 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12218987 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17672 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
59112149 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12218987 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-15880142 usd
CY2023Q1 us-gaap Depreciation
Depreciation
3290 usd
CY2022Q1 us-gaap Depreciation
Depreciation
2488 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2577187 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1988871 usd
CY2023Q1 us-gaap Pension Expense Reversal Of Expense Noncash
PensionExpenseReversalOfExpenseNoncash
-13271 usd
CY2022Q1 us-gaap Pension Expense Reversal Of Expense Noncash
PensionExpenseReversalOfExpenseNoncash
77087 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-58806 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4876 usd
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
161316 usd
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
432799 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1103606 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
847950 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3572431 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2247274 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3946173 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1345669 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9024427 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14185964 usd
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19648532 usd
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16010 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19648532 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16010 usd
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
CY2022Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
15000000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3791 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15003791 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-535 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6504 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10623570 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
795313 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39505627 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8038845 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50129197 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8834157.72 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">determining whether the in-process research and development expenditure (“IPR&amp;D”) has an alternative future use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">estimating the fair value of the portion of the aggregate purchase price relating to its own shares in connection with the acquisition of the In-License Agreement, dated April 29, 2021, by and between MoonLake AG and Merck Healthcare KGaA, Darmstadt, Germany (the “In-License Agreement”);</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">determining assumptions used in determining the fair value of share-based compensation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected.</span></div>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, or the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
100000 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
171809 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
72261 usd
CY2023Q1 mnlk Number Of Operating Leases
NumberOfOperatingLeases
1 lease
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
698556 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1416597 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12200000 usd
CY2023Q1 mnlk Current Assets In Excess Of Current Liabilities
CurrentAssetsInExcessOfCurrentLiabilities
59200000 usd
CY2023Q1 us-gaap Cash
Cash
50100000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
12900000 usd
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
47692710 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52490507 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
47277485 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
415225 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
47692710 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
415225 usd
CY2023Q1 mnlk Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
1991902 usd
CY2022Q4 mnlk Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
2443863 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
385404 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
319008 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3075862 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4179468 usd
CY2023Q1 mnlk Research And Development Services And License Fees Current
ResearchAndDevelopmentServicesAndLicenseFeesCurrent
3070454 usd
CY2022Q4 mnlk Research And Development Services And License Fees Current
ResearchAndDevelopmentServicesAndLicenseFeesCurrent
31687 usd
CY2023Q1 mnlk Supply And Manufacturing Fees Payable Current
SupplyAndManufacturingFeesPayableCurrent
510524 usd
CY2022Q4 mnlk Supply And Manufacturing Fees Payable Current
SupplyAndManufacturingFeesPayableCurrent
65979 usd
CY2023Q1 mnlk Other Accrued Consulting And Advisory Fees Current
OtherAccruedConsultingAndAdvisoryFeesCurrent
123568 usd
CY2022Q4 mnlk Other Accrued Consulting And Advisory Fees Current
OtherAccruedConsultingAndAdvisoryFeesCurrent
51658 usd
CY2023Q1 mnlk Accrued Legal And Intellectual Property Advisory Fees Payable Current
AccruedLegalAndIntellectualPropertyAdvisoryFeesPayableCurrent
58361 usd
CY2022Q4 mnlk Accrued Legal And Intellectual Property Advisory Fees Payable Current
AccruedLegalAndIntellectualPropertyAdvisoryFeesPayableCurrent
40532 usd
CY2023Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
64496 usd
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
65116 usd
CY2023Q1 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
3827403 usd
CY2022Q4 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
254972 usd
CY2023Q1 mnlk Accrued Research And Development Services And Licensing Fees Current
AccruedResearchAndDevelopmentServicesAndLicensingFeesCurrent
1912634 usd
CY2022Q4 mnlk Accrued Research And Development Services And Licensing Fees Current
AccruedResearchAndDevelopmentServicesAndLicensingFeesCurrent
5803432 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
547893 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1109734 usd
CY2023Q1 mnlk Accrued Consulting And Other Fees Current
AccruedConsultingAndOtherFeesCurrent
435923 usd
CY2022Q4 mnlk Accrued Consulting And Other Fees Current
AccruedConsultingAndOtherFeesCurrent
218021 usd
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
201389 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
109826 usd
CY2023Q1 mnlk Accrued Legal Fees Current
AccruedLegalFeesCurrent
199000 usd
CY2022Q4 mnlk Accrued Legal Fees Current
AccruedLegalFeesCurrent
15832 usd
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3296839 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7256845 usd
CY2021Q3 mnlk Operating Lease Area Of Leased Space
OperatingLeaseAreaOfLeasedSpace
2300 sqft
CY2021Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P3Y
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.008
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
117414 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
130461 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 usd
CY2023Q1 mnlk Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
0 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
247875 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1621 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
246254 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
155173 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91081 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
38825 usd
CY2023Q1 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
29802 usd
CY2022Q1 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
116165 usd
CY2023Q1 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
7442 usd
CY2022Q1 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
1302 usd
CY2023Q1 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
8871 usd
CY2022Q1 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
3998 usd
CY2023Q1 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
0 usd
CY2022Q1 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-467 usd
CY2023Q1 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
28373 usd
CY2022Q1 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
113936 usd
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
41513 usd
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
38405 chf
CY2022Q4 mnlk Shares Authorized
SharesAuthorized
600000000 shares
CY2022Q4 us-gaap Shares Issued
SharesIssued
52701111 shares
CY2023Q1 mnlk Shares Authorized
SharesAuthorized
600000000 shares
CY2023Q1 us-gaap Shares Issued
SharesIssued
52701111 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9004856 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15880142 usd
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39061977 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39061977 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5013646 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5013646 shares
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2577187 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1988871 usd
CY2023Q1 mnlk Number Of Co Founders
NumberOfCoFounders
3 co-founder
CY2023Q1 mnlk Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise
360000000 usd
CY2023Q1 mnlk Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares
1070196 shares
CY2023Q1 mnlk Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise
360000000 usd
CY2023Q1 mnlk Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares
1070196 shares
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.001
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.001
CY2023Q1 mnlk Unrecognized Commitments And Contingencies
UnrecognizedCommitmentsAndContingencies
28500000 usd

Files In Submission

Name View Source Status
0001821586-23-000012-index-headers.html Edgar Link pending
0001821586-23-000012-index.html Edgar Link pending
0001821586-23-000012.txt Edgar Link pending
0001821586-23-000012-xbrl.zip Edgar Link pending
exhibit101-10xq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0a.jpg Edgar Link pending
image_1a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mltx_2023q1xex311dasilva.htm Edgar Link pending
mltx_2023q1xex312bodenstedt.htm Edgar Link pending
mltx_2023q1xex321dasilva.htm Edgar Link pending
mltx_2023q1xex322bodenstedt.htm Edgar Link pending
mnlk-20230331.htm Edgar Link pending
mnlk-20230331.xsd Edgar Link pending
opinion-51.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mnlk-20230331_cal.xml Edgar Link unprocessable
mnlk-20230331_def.xml Edgar Link unprocessable
mnlk-20230331_lab.xml Edgar Link unprocessable
mnlk-20230331_pre.xml Edgar Link unprocessable
mnlk-20230331_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending